Renfu Pharmaceuticals: HW241045 Tablets Received Drug Clinical Trial Approval Notification Letter.

Renfu Pharmaceuticals announced that its wholly-owned subsidiary, the Innovative Drug R&D Center, has received the Drug Clinical Trial Approval Notice for HW241045 tablets issued by the National Medical Products Administration, allowing clinical trials for idiopathic pulmonary fibrosis indications. HW241045 tablets are Class 1 chemical drugs, and there are currently no drugs with the same target approved for marketing worldwide. The cumulative research and development investment in this project by the Innovative Drug R&D Center is approximately 23 million RMB.